Seattle Genetics, Inc. and Agensys, Inc., an Affiliate of Astellas Pharma Inc., Announce Co-Development of an Additional Antibody-Drug Conjugate (ADC) Under Existing Collaboration
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies’ existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME.
Help employers find you! Check out all the jobs and post your resume.
BOTHELL, Wash. & SANTA MONICA, Calif.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. (Tokyo:4503), today announced that Seattle Genetics has exercised an option to co-develop an additional antibody-drug conjugate (ADC) under the companies’ existing ADC collaboration agreement. The ADC, called ASG-15ME, targets the tumor antigen SLITRK6, which is known to be expressed on bladder and lung cancer. Agensys has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 1 trial of ASG-15ME.
Help employers find you! Check out all the jobs and post your resume.